The dysregulated Type 2 immune response drives AD
Three types of immune response play a natural protective role against different pathogens, the Type 2 immune response drives AD specifically2-4
Type 2 inflammation, due to increased signalling of IL-4 and IL-13, contributes to the clinical disease features of AD4–6
Dysregulation of the Type 2 immune response5,7
Leads to increased signalling and production of IL-4 and IL-135
Which drives and perpetuates Type 2 inflammation5
Resulting in the clinical disease features of AD:4,6
• Skin barrier dysfunction
• Skin lesions
• Itch
• Increased susceptibility to skin infections
Selectively targeting a single signalling receptor, the IL-4Rα, thereby inhibiting IL-4 and IL-13 signalling, can help to reduce the persistent underlying Type 2 inflammation in AD8
Learn more about the pathophysiology of AD
Inflammatory pathways
What are the main inflammatory pathways involved in the disease? Find out about the pathway involved in AD.
Find out more
- DUPIXENT Summary of Product Characteristics. September 2021.
- Leung DYM, et al. J Clin Invest. 2004;113(5):651–657.
- Suárez-Fariñas M, et al. J Allergy Clin Immunol. 2011;127(4):954–964.
- Gittler JK, et al. J Allergy Clin Immunol. 2012;130(6):1344–1354.
- Gandhi NA, et al. Nat Rev Drug Discov. 2016;15:35–50.
- Biedermann T, et al. Front Immunol. 2015;6:353.
- Artis D & Spits H. Nature. 2015;517:293–301.
- Guttman-Yassky E, et al. J Allergy Clin Immunol. 2019;143:155– 172.
AD, atopic dermatitis; IL, interleukin; IL-4Rα, interleukin 4 receptor alpha; ILC, innate lymphoid cells; Th, T-helper cells.
References
MAT-IE-2101040(v4.0) | Date of preparation: February 2022